Skip to NavigationSkip to content

EpiCast Report: Psoriasis - Epidemiology Forecast to 2024 - ref #GB000051

EpiCast Report: Psoriasis - Epidemiology Forecast to 2024

Psoriasis is a chronic, immune-mediated inflammatory skin disease. Psoriasis ranges in severity from a few scattered, sharply demarcated, scaly, red, coin-sized skin lesions or scaly plaques to involvement of almost the entire body surface. Psoriasis is more prevalent in colder areas, and less prevalent in the tropics and warmer regions of the world. Globally, the one-year prevalence of psoriasis varies with the differences in prevalence of psoriasis attributed to variations in environmental factors, genetic factors, and differences in the case definition used to diagnose psoriasis in epidemiology studies.

GlobalData epidemiologists forecast an increase in the one-year diagnosed prevalent cases of psoriasis in the 8MM, from 43,747,201 cases in 2014 to 50,455,013 cases in 2024, with an Annual Growth Rate (AGR) of 1.53% during the forecast period. In 2024, India will have the highest number of one-year diagnosed prevalent cases of psoriasis in the 8MM, with 32,853,676 cases, whereas Japan will have the lowest number of one-year diagnosed prevalent cases of psoriasis, with 482,431 cases in 2024.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for psoriasis in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and India). The report also provides a 10-year epidemiological forecast of the one-year diagnosed prevalent cases of psoriasis segmented by sex, age (at 10-year intervals, starting at age zero years and ending at ages =80 years), and severity (mild, moderate, and severe) in the 8MM.

Scope

- The Psoriasis EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for psoriasis in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and India). The report also provides a 10-year epidemiological forecast of the one-year diagnosed prevalent cases of psoriasis segmented by sex, age (at 10-year intervals, starting at age zero years and ending at ages =80 years), and severity (mild, moderate, and severe) in the 8MM. GlobalData epidemiologists forecast the one-year diagnosed prevalent cases of psoriasis in the 8MM from 2014–2024 using data obtained from peer-reviewed journals that provide one-year diagnosed prevalence of psoriasis in the respective markets. Psoriasis one-year diagnosed prevalent cases are further segmented by severity.
- The psoriasis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Psoriasis EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global psoriasis market.
- Quantify patient populations in the global psoriasis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for psoriasis therapeutics in each of the markets covered.

Publisher: GlobalData
Publication date: October 2015

Price: £ 2,632.70

You need to agree to the Terms and Conditions before placing your order

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches